Company profile
Clearside Biomedical, Inc.
OTC: CLSDQ · Healthcare · Biotechnology
#822 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 49GM —SS 42
v0.1 · 25/100 weight · pillars only
↑ filing timeliness, listing tenure · ↓ Piotroski F, revenue growth (YoY)
Methodology →Revenue TTM
$3.3M
Rev growth YoY (TTM)
-56.8%
Net income (FY)
-$34.4M
Employees
32
as of 2026-08-26
Market cap
$1.3M
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.7M$1.7M2024
Net income-$34.4M-$34.4M2024
Operating income-$28.9M-$28.9M2024
Total assets$25.1M$25.1M2024
Liabilities$64.0M$64.0M2024
Equity-$38.9M-$38.9M2024
Revenue trend
FY2018 – FY2024 · USD
FY18
FY18
FY19
FY20
FY21
FY22
FY23
FY24
Revenue by segment
Filed disclosures · FY2024
By product
License71%
Product and Service, Other29%
By geography
Not disclosed.
The read
What is Clearside Biomedical, Inc.’s revenue?
Clearside Biomedical, Inc. booked $1.7M in FY2024 revenue, contracting 80% year over year — slower than 88% of Healthcare companies we track, at a -2064.4% net margin.
Peers · Healthcare
CanaFarma Hemp Products Corp.——Spectral Medical Inc31DVolitionRX Ltd40DRani Therapeutics Holdings, Inc.41DEBR Systems, Inc.34DJames E. Wagner Cultivation Corporation——Neighbors
Fulton →Key facts
CEOGeorge Lasezkay
SectorHealthcare
IndustryBiotechnology
HeadquartersAlpharetta, GA
ExchangeOTC: CLSDQ
Employees32
IPO date2016-06-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.